menu
    • menu
    [{"orgOrder":0,"company":"MabGenesis","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Collaborates with MabGenesis to Discover & Develop Novel Monoclonal Antibodies in Canine","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"MabGenesis","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MabGenesis \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"MabGenesis \/ Boehringer Ingelheim"}]

    Find Clinical Drug Pipeline Developments & Deals by MabGenesis

    Menu

    MabGenesis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MabGenesis

                            Japan arrow
                            FNCE 2024
                            Not Confirmed

                            MabGenesis

                            Japan arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Monoclonal Antibody

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Boehringer Ingelheim Collaborates with MabGenesis to Discover & Develop Novel Monoclonal Antibodies in Canine

                            Details : Under the agreement, MabGenesis will apply its unique platform to the discovery of first-in-class candidate antibodies against targets of interest selected by Boehringer Ingelheim.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 18, 2022

                            Lead Product(s) : Monoclonal Antibody

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth